Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised PR Event in connection with the acquisition of the golf tournament Nordea Masters
Mandate

Vinge has advised PR Event in connection with the acquisition of the golf tournament Nordea Masters

September 27, 2013

Vinge has acted for PR Event i Båstad AB in connection with the acquisition of the golf tournament Nordea Masters by way of an asset transfer from Scandinavian Masters AB. PR Event is part of the Lagardère Unlimited Group, active within e.g. events production and management, marketing rights and  the talent representation business. Nordea Masters forms part of the European Tour and is with its 50 000 visitors per year Sweden’s largest recurring sports event. Closing of the transaction took place on 24 September 2013.

Partner Michael Wigge and associates Peter Sundgren and Sofie Bjärtun (M&A) acted for PR Event in connection with the transaction together with, among others, specialists Christian Hybbinette (Commercial Agreements) and Fredrik Gustafsson (Employment).    

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

 Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026